Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AMICUS THERAPEUTICS, INC. Investor Presentation 2014

Jan 13, 2014

31523_rns_2014-01-13_5890c6b9-989e-4985-814b-f9850c4cdec9.zip

Investor Presentation

Open in viewer

Opens in your device viewer

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934*

Date of Report (Date of earliest event reported): January 13, 2014

*AMICUS THERAPEUTICS, INC.*

(Exact Name of Registrant as Specified in Its Charter)

*Delaware*

(State or Other Jurisdiction of Incorporation)

001-33497 71-0869350
(Commission File Number) (IRS Employer Identification No.)
1 Cedar Brook Drive, Cranbury, NJ 08512
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\108183\14-3052-2\task6449438\3052-2-ba.htm',USER='108183',CD='Jan 13 10:20 2014'

*Item 8.01 — Other Events.*

The senior management of Amicus Therapeutics, Inc. (the “Company”) is using the presentation attached as Exhibit 99.1 to this Current Report in its current meetings with investors and analysts. In addition, on January 13, 2014, the Company filed a press release, a copy of which is attached to this Current Report as Exhibit 99.2.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\108183\14-3052-2\task6449438\3052-2-ba.htm',USER='108183',CD='Jan 13 10:20 2014'

*Item 9.01. Financial Statements and Exhibits.*

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

Exhibit Number Description
99.1 Presentation Materials
99.2 Press Release dated January 13, 2014

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\108183\14-3052-2\task6449438\3052-2-ba.htm',USER='108183',CD='Jan 13 10:20 2014'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ William D. Baird III
William D. Baird III
Chief Financial Officer

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\108183\14-3052-2\task6449438\3052-2-ba.htm',USER='108183',CD='Jan 13 10:20 2014'

*EXHIBIT INDEX*

Exhibit Number Description
99.1 Presentation Materials
99.2 Press Release dated January 13, 2014

5

SEQ.=1,FOLIO='5',FILE='C:\JMS\108183\14-3052-2\task6449438\3052-2-ba.htm',USER='108183',CD='Jan 13 10:20 2014'